Since the introduction of targeted therapies against vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathway in the 2000s, the International Metastatic RCC Database Consortium (IMDC) criteria, including neutrophil and platelet counts, PS, hemoglobin, calcium, and time from initial diagnosis to systemic therapy, replaced the position of the prognostic model [4]. The gene discussed is MTOR; the disease is renal cell carcinoma.